Sorafenib Maintenance in Patients with FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: an Open-Label, Multicentre, Randomised Phase 3 Trial
Li Xuan,Yu Wang,Kaibo Yang,Ruoyang Shao,Fen Huang,Zhiping Fan,Peiru Chi,Yajing Xu,Na Xu,Lan Deng,Xudong Li,Xinquan Liang,Xiaodan Luo,Pengcheng Shi,Hui Liu,Zhixiang Wang,Ling Jiang,Ren Lin,Yan Chen,Sanfang Tu,Yu Zhang,Jing Sun,Xiaojun Huang,Qifa Liu
DOI: https://doi.org/10.1016/s1470-2045(20)30455-1
IF: 54.433
2020-01-01
The Lancet Oncology
Abstract:Background Our open-label, multicentre, randomised, phase 3 trial showed that sorafenib maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall survival and reduced relapse for patients with FLT3 internal tandem duplication (FLT3-ITD) acute myeloid leukaemia undergoing allogeneic HSCT. Here, we present a post-hoc analysis on the 5-year follow-up data of this trial.Methods This phase 3 trial, done in seven hospitals in China, included patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic HSCT, who were aged 18-60 years, had an Eastern Cooperative Oncology Group performance status of 0-2, had composite complete remission before and after transplantation, and had haematopoietic recovery within 60 days after transplantation. Patients were randomly assigned (1:1) to receive sorafenib maintenance (400 mg orally twice daily) or non-maintenance (control) at 30-60 days after transplantation. Randomisation was done with permuted blocks (block size four) via an interactive web-based system. Investigators and participants were not masked to group assignment. The primary endpoint was the 1-year cumulative incidence of relapse, which was reported previously. For this updated analysis, the 5-year endpoints were overall survival; cumulative incidence of relapse; non-relapse mortality; leukaemia-free survival; graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS); cumulative incidence of chronic GVHD; and late effects in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT02474290, and is complete. Findings Between June 20, 2015, and July 21, 2018, 202 patients were randomly assigned to sorafenib maintenance (n=100) or non-maintenance (n=102). Median follow-up was 60 & BULL;4 months (IQR 16 & BULL;7-73 & BULL;3). Extended follow-up showed improved overall survival (72 & BULL;0% [95% CI 62 & BULL;1-79 & BULL;7] vs 55 & BULL;9% [45 & BULL;7-64 & BULL;9]; hazard ratio [HR] 0 & BULL;55, 95% CI 0 & BULL;34-0 & BULL;88; p=0 & BULL;011), leukaemia-free survival (70 & BULL;0% [60 & BULL;0-78 & BULL;0] vs 49 & BULL;0% [39 & BULL;0-58 & BULL;3]; 0 & BULL;47, 0 & BULL;30-0 & BULL;73; p=0 & BULL;0007), and GRFS (58 & BULL;0% [47 & BULL;7-67 & BULL;0] vs 39 & BULL;2% [29 & BULL;8-48 & BULL;5]; 0 & BULL;56, 0 & BULL;38-0 & BULL;83; p=0 & BULL;0030), lower cumulative incidence of relapse (15 & BULL;0% [8 & BULL;8-22 & BULL;7] vs 36 & BULL;3% [27 & BULL;0-45 & BULL;6]; 0 & BULL;33, 0 & BULL;18-0 & BULL;60; p=0 & BULL;0003), and no increase in non-relapse mortality (15 & BULL;0% [8 & BULL;8-22 & BULL;7] vs 14 & BULL;7% [8 & BULL;6-22 & BULL;3]; 0 & BULL;79, 0 & BULL;39-1 & BULL;62; p=0 & BULL;98) for patients in the sorafenib group compared with those in the control group. The 5-year cumulative incidence of chronic GVHD (54 & BULL;0% [43 & BULL;7-63 & BULL;2] vs 51 & BULL;0% [40 & BULL;8-60 & BULL;3]; 0 & BULL;82, 0 & BULL;56-1 & BULL;19; p=0 & BULL;73) did not differ significantly between the two groups and we did not find substantial differences in late effects between the two groups. There were no treatment-related deaths.Interpretation With extended follow-up, sorafenib maintenance after transplantation is associated with improved long-term survival and reduced relapse rates compared with non-maintenance, further supporting this strategy as a standard of care for patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic HSCT. Copyright & COPY; 2023 Elsevier Ltd. All rights reserved.